Antibody-Drug Conjugate and RAS Inhibitor Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using anti-HER2 antibody-drug conjugates and RASG12C inhibitors have limitations in terms of efficacy, durability of therapeutic response, and tolerance, particularly in reducing dose-dependent toxicity.
Innovation Solution
The combination of an anti-HER2 antibody-drug conjugate, such as trastuzumab deruxtecan, with a RASG12C inhibitor, administered together to enhance antitumor effects, increase treatment durability, and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-HER2 antibody-drug conjugate and RASG12C inhibitor are administered in combination, then antitumor efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent combines anti-HER2 antibody-drug conjugate and RASG12C inhibitor into a single pharmaceutical composition that can be administered together, merging two separate treatment regimens into one unified therapy to improve antitumor efficacy while managing treatment complexity
2Reliability
If higher doses of single agents are used to improve efficacy, then antitumor effect increases, but dose-dependent toxicity increases
Solution Approach 1:
The patent changes the dosing parameters by administering anti-HER2 antibody-drug conjugate and RASG12C inhibitor in combination at optimized doses, rather than using higher doses of single agents, thereby achieving improved antitumor effect while reducing dose-dependent toxicity through synergistic interaction
Data Source
AI summary
A pharmaceutical product for administration of an anti HER2 antibody-drug conjugate in combination with a RASG12C inhibitor is provided. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the RASG12C inhibitor are administered in combination to a subject.